Download PDF
Thromb Haemost 2013; 109(01): 16-23
DOI: 10.1160/TH12-05-0332
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients

Dietje E. Fransen van de Putte
1   Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Kathelijn Fischer
1   Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
2   Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
,
Michael Makris
3   Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK
,
Campbell R. Tait
4   West of Scotland Haemophilia and Thrombosis Centre, Royal Infirmary, Glasgow, UK
,
Pratima Chowdary
5   Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK
,
Peter W. Collins
6   Arthur Bloom Haemophilia Centre, School of Medicine, Cardiff University and University Hospital of Wales, Cardiff, UK
,
Karina Meijer
7   Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Center Groningen, Groningen, The Netherlands
,
Goris Roosendaal
1   Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Roger E. G. Schutgens
1   Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Eveline P. Mauser-Bunschoten
1   Van Creveldkliniek, Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
› Author Affiliations Financial support: This study was supported by an unrestricted grant from CSL Behring to DEFvdP.
Further Information

Publication History

Received: 20 May 2012

Accepted after minor revision: 17 September 2012

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Summary

Cardiovascular disease (CVD) mortality is reported to be decreased in haemophilia patients, but reports on the prevalence of CVD risk factors are conflicting. A cross-sectional assessment of CVD risk profiles was performed in a large cohort of haemophilia patients. Baseline data on CVD risk factors of 709 Dutch and UK haemophilia patients aged ≥ 30 years were analysed and compared with the general age-matched male population. CVD risk profiles were assessed using the QRISK®2–2011 and SCORE algorithms. Although QRISK®2 was only validated in the UK, comparison with SCORE indicated similar properties of QRISK®2 in both Dutch and UK patients (correlation 0.86). Mean age was 49.8 years. Hypertension was more common in haemophilia patients than in the general population (49% vs. 40%), while the prevalences of obesity and hypercholesterolaemia were lower (15 vs. 20% and 44 vs. 68%, respectively), and those of diabetes and smoking were similar. The predicted 10-year QRISK®2 risk was significantly higher in haemophilia patients than in the general population (8.9 vs. 6.7%), indicating more unfavourable cardiovascular disease risk profiles. This increased risk became apparent after the age of 40 years. Our results indicate an increased prevalence of hypertension and overall more unfavourable CVD risk profiles in haemophilia patients compared with the general age-matched male population.

Keywords

Cardiovascular disease - haemophilia - hypertension - QRISK - risk profile
 

  • References

  • 1 Plug I. et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 04: 510-516. DOI:10.1111/j.1538-7836.2006.01808.x.
    CrossrefPubMedGoogle Scholar
  • 2 Darby SC. et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-825. DOI:10.1182/blood-2006-10-050435.
    CrossrefPubMedGoogle Scholar
  • 3 Koumbarelis E. et al. Epidemiology of haemophilia in Greece: an overview. Thromb Haemost 1994; 72: 808-813.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Rosendaal FR. et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75: 525-530. DOI:10.1111/j.1365-2141.1990.tb07793.x.
    CrossrefPubMedGoogle Scholar
  • 5 Siboni SM. et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost 2009; 07: 780-786. DOI:10.1111/j.1538-7836.2009.03318.x.
    CrossrefPubMedGoogle Scholar
  • 6 Biere-Rafi S. et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278. DOI:10.1160/TH10-07-0460.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Lim MY, Pruthi RK. Cardiovascular disease risk factors: prevalence and management in adult hemophilia patients. Blood Coagul Fibrinolysis 2011; 22: 402-406. DOI:10.1097/MBC.0b013e328345f582.
    CrossrefPubMedGoogle Scholar
  • 8 Bilora F. et al. Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost 2006; 12: 193-198. DOI:10.1177/107602960601200207.
    CrossrefPubMedGoogle Scholar
  • 9 Foley CJ. et al. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 08: 208-211. DOI:10.1111/j.1538-7836.2009.03669.x.
    CrossrefPubMedGoogle Scholar
  • 10 Walsh M. et al. Health-related quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost 2008; 06: 755-761. DOI:10.1111/j.1538-7836.2008.02929.x.
    CrossrefPubMedGoogle Scholar
  • 11 Hofstede FG. et al. Obesity: a new disaster for haemophilic patients? A nationwide survey. Haemophilia 2008; 14: 1035-1038. DOI:10.1111/j.1365-2516.2008.01806.x.
    CrossrefPubMedGoogle Scholar
  • 12 Fransen van de Putte DE. et al. Non-fatal cardiovascular disease, malignancies and other co-morbidity in adult haemophilia patients. Thromb Res 2012; 130: 157-162. DOI:10.1016/j.thromres.2011.12.012.
    CrossrefPubMedGoogle Scholar
  • 13 Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens 2006; 24: 1187-1192. DOI:10.1097/01.hjh.0000226210.95936.bc.
    CrossrefPubMedGoogle Scholar
  • 14 Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. Br Med J 2010; 340: c2442. DOI:10.1136/bmj.c2442.
    CrossrefPubMedGoogle Scholar
  • 15 Hippisley-Cox J. et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Br Med J 2007; 335: 136. DOI:10.1136/bmj.39261.471806.55.
    CrossrefPubMedGoogle Scholar
  • 16 Hippisley-Cox J. et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Br Med J 2008; 336: 1475-1482. DOI:10.1136/bmj.39609.449676.25.
    CrossrefPubMedGoogle Scholar
  • 17 Conroy RM. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. DOI:10.1016/S0195-668X(03)00114-3.
    CrossrefPubMedGoogle Scholar
  • 18 Sharathkumar AA. et al. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia 2011; 17: 597-604. DOI:10.1111/j.1365-2516.2010.02463.x.
    CrossrefPubMedGoogle Scholar
  • 19 Wisniewska-Ligier M. et al. Lipid metabolism in children with chronic hepatitis C, A preliminary report. Hepatogastroenterology 2006; 53: 887-891.
    PubMedGoogle Scholar
  • 20 Dai CY. et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49: 9-16. DOI:10.1016/j.jhep.2008.03.016.
    CrossrefPubMedGoogle Scholar
  • 21 Berger JS. et al. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010; 55: 1169-1177. DOI:10.1016/j.jacc.2009.09.066.
    CrossrefPubMedGoogle Scholar
  • 22 Dent TH. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis 2010; 213: 345-351. DOI:10.1016/j.atherosclerosis.2010.06.019.
    CrossrefPubMedGoogle Scholar